An Observational Study Examining the Effect of Added MabThera Therapy in Patients With Untreated Chronic Lymphocytic Leukemia
Last updated on April 2022Recruitment
- Recruitment Status
- Completed
- Estimated Enrollment
- 200
Inclusion Criteria
- Diagnosed with first-line CLL having received only 1 cycle of MabThera chemotherapy
- aged >/= 18 years
- Diagnosed with first-line CLL having received only 1 cycle of MabThera chemotherapy
- aged >/= 18 years
Exclusion Criteria
- Receipt of an investigational drug within 30 days prior to entering the study
- Pregnant or breast-feeding
- Receipt of an investigational drug within 30 days prior to entering the study
- Pregnant or breast-feeding
Summary
- Conditions
- Chronic Lymphocytic Leukemia
- Type
- Observational
- Design
- Observational Model: Case-Only
- Time Perspective: Prospective
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Inclusion Criteria
- Diagnosed with first-line CLL having received only 1 cycle of MabThera chemotherapy
- aged >/= 18 years
- Diagnosed with first-line CLL having received only 1 cycle of MabThera chemotherapy
- aged >/= 18 years
Exclusion Criteria
- Receipt of an investigational drug within 30 days prior to entering the study
- Pregnant or breast-feeding
- Receipt of an investigational drug within 30 days prior to entering the study
- Pregnant or breast-feeding
Tracking Information
- NCT #
- NCT02080884
- Collaborators
- Not Provided
- Investigators
- Study Director: Clinical Trials Hoffmann-La Roche
Get Well Soon